Nuvation Bio Inc. (NYSE: NUVB), a global oncology company tackling some of the toughest challenges in cancer treatment, today ...

Nuvation Bio (NUVB) delivered earnings and revenue surprises of 0.00% and +93.32%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it will host a conference call and webcast on ...

FDA approval of IBTROZI (taletrectinib) transformed Nuvation Bio into a commercial-stage company, driving $4.8 million in GAAP revenue, well above GAAP revenue estimates. Earnings per share (GAAP) was ...

NEW YORK--(BUSINESS WIRE)-- Nuvation Bio Inc. (NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it will host a conference ...

Nuvation Bio Inc. (NYSE:NUVB) is one of the penny stocks that will skyrocket. On June 24, the company confirmed the addition of its Taletrectinib (IBTROZI) treatment as a Preferred Agent in the ...

Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that new data will be presented at the IASLC 2025 ...

Nuvation Bio Inc. (NYSE: NUVB) is one of the penny stocks that will skyrocket. On June 24, the company confirmed the addition of its Taletrectinib (IBTROZI) treatment as a Preferred Agent in the ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aclaris Therapeutics (ACRS – Research Report) and Nuvation Bio (NUVB – Research Report) with ...

Baystreet.ca News Commentary – In the United States, federal budget cuts threaten to slow the nation’s progress in the fight against cancer, but the private sector appears ...

Nuvation Bio Inc. (NYSE:NUVB) is one of the best biotech penny stocks to buy right now. In a report released on July 7, Leonid Timashev from RBC Capital maintained a Buy rating on Nuvation Bio Inc.